Summary of The Oncology Institute (TOIIW) Q4 2025 Earnings Call

1Key Financial Results and Metrics

Revenue Growth: Q4 revenue reached $142 million, up 41.6% year-over-year. Full-year revenue increased approximately 28% to $502.7 million, surpassing $500 million for the first time.

Adjusted EBITDA: The company reported its first profitable quarter from an adjusted EBITDA perspective, achieving $147,000 in Q4, a significant improvement from a loss of $7.8 million in Q4 2024.

Gross Profit: Q4 gross profit was $22.7 million, with a gross margin of 16%, compared to 14.6% in the prior year. Pharmacy revenue grew 71.1% year-over-year to $81.4 million.

Cash Position: Ended Q4 with $33.6 million in cash and positive operating cash flow of $3.2 million.

2Strategic Updates and Business Highlights

Capitated Care Model Expansion: The company initiated nine new capitated contracts in 2025, adding approximately 260,000 patient lives under management. The partnership with Elevance in Florida is expected to double in size in 2026.

Pharmacy Platform Growth: The Part D dispensing platform generated nearly $270 million in revenue, contributing close to $50 million in gross profit for the year.

Operational Efficiency: SG&A expenses decreased by 2% year-over-year, reflecting improved operational efficiency as the company scales.

Leadership Strengthening: New appointments in the leadership team are expected to enhance growth execution.

3Forward Guidance and Outlook

2026 Revenue Guidance: TOI expects revenue between $630 million to $650 million, with approximately $150 million from capitated revenue.

Adjusted EBITDA: Guidance for adjusted EBITDA is between $0 million to $9 million, with expectations of achieving free cash flow positivity by the end of 2026.

Capitated Revenue Growth: The company anticipates over 80% growth in capitated revenue for 2026.

4Bad News, Challenges, or Points of Concern

Inflation Reduction Act Impact: While the impact on IMBRUVICA is expected to be minor, there are concerns about potential pressures on margins due to maximum fair price negotiations.

First Quarter Challenges: The first quarter of 2026 is expected to be seasonally weak, with anticipated adjusted EBITDA losses between $3 million to $1 million due to patient deductible resets and annual drug price increases.

Market Competition: There are concerns about the competitive landscape, particularly regarding how TOI will maintain margins in a potentially lower rate environment for Medicare Advantage.

5Notable Q&A Insights

Dispensing Revenue Drivers: Strong performance in Q4 was attributed to operational execution and increased patient encounters linked to capitated contracts.

Capitated Contracts: The new contracts with Humana and CarePlus in Florida were highlighted as significant wins, with expectations of substantial growth potential in those markets.

AI Efficiency Gains: The company expects AI-related efficiencies to generate approximately $2 million in SG&A savings in 2026, with ongoing improvements in operational metrics.

Market Positioning: Management emphasized that TOI's unique care model allows for better control over practice patterns and competitive pricing, positioning the company favorably in a challenging market environment. Overall, TOI demonstrated strong growth and operational improvements in 2025, with a positive outlook for 2026, despite some anticipated challenges related to market conditions and regulatory impacts.